Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,524.40GBp
4:35pm BST
Change (% chg)

-16.40 (-1.06%)
Prev Close
1,540.80
Open
1,526.80
Day's High
1,536.20
Day's Low
1,523.20
Volume
5,924,105
Avg. Vol
7,769,216
52-wk High
1,648.80
52-wk Low
1,395.80

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 0.98
Market Cap(Mil.): £76,849.60
Shares Outstanding(Mil.): 4,987.64
Dividend: 23.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 20.44 58.59 59.19
EPS (TTM): 0.75 -- --
ROI: 13.34 12.14 11.77
ROE: 174.65 13.10 12.61

GSK wins U.S. nod for two-drug HIV combination

GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

08 Apr 2019

GSK wins U.S. nod for two-drug HIV combination

GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

08 Apr 2019

UPDATE 2-GSK wins U.S. nod for two-drug HIV combination

April 8 GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

08 Apr 2019

U.S. FDA approves GSK's two-drug HIV treatment

April 8 The U.S. Food and Drug Administration said on Monday it had approved GlaxoSmithKline Plc's two-drug HIV treatment.

08 Apr 2019

GSK reports positive data for experimental blood cancer drug

GlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer.

21 Mar 2019

GSK reports positive data for experimental blood cancer drug

March 21 GlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer.

21 Mar 2019

GSK reports positive data from trial of endometrial cancer drug

GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

19 Mar 2019

GSK reports positive data from trial of endometrial cancer drug

GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

19 Mar 2019

GSK reports positive data from trial of endometrial cancer drug

March 19 GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

19 Mar 2019

British fraud office abandons Rolls-Royce, GSK investigations

LONDON The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".

22 Feb 2019

Earnings vs. Estimates